 Home > Medical News > Latest Medical News > Yangzijiang Pharmaceutical reached new cooperation and introduced two innovative biological drugs

Yangzijiang Pharmaceutical reached new cooperation and introduced two innovative biological drugs

 Last Update: 2021-05-31
 Source: Internet
 Author: User

Tags

cells antibodies

new pharmaceutical companies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

News on May 27th, Yangtze River Pharmaceutical and Maiwei Biotechnology have reached a cooperation on the rights and interests of two innovative biological drugs under development in China, one of which is recombinant (yeast secreted) human serum albumin-human granulocytes for injection Colony stimulating factor fusion protein (8MW0511); the other is recombinant humanized anti-PD-1 monoclonal antibody injection (9MW1111).

8MW0511 was developed by Jiangsu Taikang Biopharmaceutical, a subsidiary of Maiwei Biology, and is currently in phase 2/3 clinical development.

It is used to prevent and treat leukopenia caused by bone marrow suppression and leukopenia in patients with bone marrow failure.

9MW1111 is a recombinant humanized anti-PD-1 monoclonal antibody developed by Maiwei Biotechnology.

By binding to PD-1 on the surface of T cells, it blocks the binding of PD-1 to ligands PD-L1 and PD-L2, thereby eliminating the immunosuppression of PD-1 signaling pathways and restoring the immunity of T cells from attacking tumor cells Features.

According to the agreement, Yangzijiang Pharmaceutical will obtain the exclusive production and commercialization rights of 8MW0511 in the cooperation area and the exclusive development, production and commercialization rights of 9MW1111 in the cooperation area in the future.

Regarding 9MW1111, Yangtze River Pharmaceutical will also obtain the exclusive right to develop drugs in combination with any other one or more drugs, and Maiwei Bio will retain all rights to develop double antibodies, polyclonal drugs and other forms of drugs.

Note: The original text has been deleted

Reference materials:

[1] Maiwei Biological and Yangzijiang Pharmaceutical reached a strategic cooperation on the domestic rights and interests of two innovative biological drugs.

Retrieved May 27, 2021, from https://mp.
weixin.

8MW0511 was developed by Jiangsu Taikang Biopharmaceutical, a subsidiary of Maiwei Biology, and is currently in phase 2/3 clinical development.

It is used to prevent and treat leukopenia caused by bone marrow suppression and leukopenia in patients with bone marrow failure.

9MW1111 is a recombinant humanized anti-PD-1 monoclonal antibody developed by Maiwei Biotechnology.

Note: The original text has been deleted

Reference materials:

[1] Maiwei Biological and Yangzijiang Pharmaceutical reached a strategic cooperation on the domestic rights and interests of two innovative biological drugs.

Retrieved May 27, 2021, from https://mp.
weixin.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.